
#277 ãèã®ãã¡ãªã¹ã¿ã·ã¹ãïŒãšã³ãã«ã³ãããã€ãã·ã¹ãã ãšççã±ã¢ã®å šè²
ã¯ããã«
ç®èç§åŠã®åéã«ãããŠãè¿å¹Žãã£ãšã泚ç®ãéããŠããæŠå¿µã®äžã€ãããšã³ãã«ã³ãããã€ãã·ã¹ãã ïŒECSïŒãã§ãããã€ãŠã¯ç¥çµç³»ã«ãããäŒéã·ã¹ãã ãšããŠã®ã¿èªèãããŠããECSã§ãããææ°ã®ç ç©¶ã«ãããç®èã®å¥åº·ç¶æãããªã¢æ©èœã®èª¿æŽããããŠççåå¿ã®æå¶ã«ãããŠäžå¿çãªåœ¹å²ãæãããŠããããšãæããã«ãªã£ãŠããŸããã
æ¬èšäºã§ã¯ãç®èã«ãããECSã®ã¡ã«ããºã ãšããããã©ã®ããã«èãã©ãã«ã®è§£æ±ºã«é¢äžããŠããã®ãããä¿¡é Œã§ããç§åŠçæ ¹æ ã«åºã¥ããŠè©³çްã«è§£èª¬ããŸãã
1. ãšã³ãã«ã³ãããã€ãã·ã¹ãã ïŒECSïŒã®åºæ¬æ§é
1.1 äœå 調æŽã®åžä»€å¡
ãšã³ãã«ã³ãããã€ãã·ã¹ãã ïŒECSïŒãšã¯ãç§ãã¡ãçãŸãã€ãæã£ãŠãã身äœèª¿æŽæ©èœã®äžã€ã§ããããã¯ãå šèº«ã®çްèéã®ã³ãã¥ãã±ãŒã·ã§ã³ãåžããããã¡ãªã¹ã¿ã·ã¹ïŒæåžžæ§ïŒããç¶æããããã«åããŠããŸãããã¡ãªã¹ã¿ã·ã¹ãšã¯ãå€éšç°å¢ãå€åããŠãäœå ã®ç¶æ ãäžå®ã«ä¿ãšããšããåãã®ããšã§ãäœæž©èª¿æŽãå ç«ãã©ã³ã¹ãªã©ãããã«å«ãŸããŸãã
1.2 ECSãæ§æãã3ã€ã®èŠçŽ
ECSã¯äž»ã«ä»¥äžã®3ã€ã®èŠçŽ ã§æ§æãããŠããŸãããããã¯éµãšéµç©Žã®é¢ä¿ã«äŸããããŸãã
ã«ã³ãããã€ãå容äœïŒéµç©ŽïŒïŒ 现è衚é¢ã«ããåãç¿ã§ããäž»èŠãªãã®ã«CB1ãšCB2ããããŸãã
ãšã³ãã«ã³ãããã€ãïŒéµïŒïŒ äœå ã§äœãããççæŽ»æ§è質ã§ãã代衚çãªãã®ã«ã¢ãã³ãããïŒAEAïŒãš2-ã¢ã©ãããã€ã«ã°ãªã»ããŒã«ïŒ2-AGïŒããããŸãã
代è¬é µçŽ ïŒ åœ¹ç®ãçµãããšã³ãã«ã³ãããã€ããåè§£ããé µçŽ ã§ãã
ç®èã«ãããŠããããã®å容äœããªã¬ã³ãïŒçµåç©è³ªïŒã¯ã衚ç®ã®è§å现èïŒã±ã©ãããµã€ãïŒãç®èè ºçŽ°èãæ¯å ããããŠæèŠç¥çµãªã©ãã»ãŒãã¹ãŠã®äž»èŠãªçްèã«ååšããŠããããšã確èªãããŠããŸãã
2. ç®èã«ãããECSã®å ·äœçãªåã
ç®èã«ãããECSã¯ãåãªãä¿¡å·äŒé以äžã®åœ¹å²ãæãããŠããŸããããã¯èã®ã管çè ããšããŠãéå°ãªåå¿ãæããäžè¶³ããŠããæ©èœãè£ãããã«åããŸãã
2.1 衚ç®çްèã®ååãšããªã¢æ©èœã®åœ¢æ
èã®æãå€åŽã«ãã衚ç®ã¯ãå€éšåºæ¿ããäœãå®ãããªã¢ã®åœ¹å²ãæãããŠããŸããECSã¯ãã®ããªã¢æ©èœã®åœ¢æã«æ·±ãé¢äžããŠããŸãã
è§å现èã«ãããCB1å容äœã®æŽ»æ§åã¯ã现èã®ååãä¿é²ããäžå€«ãªè§å±€ãäœãæå©ããããŸãããŸãã现èéè質ïŒã»ã©ãããªã©ïŒã®åæã調æŽããèã®æ°Žåä¿æèœåã«åœ±é¿ãäžããããšã瀺åãããŠããŸããECSã®åããä¹±ãããšãèã®ä¹Ÿç¥ãããªã¢æ©èœã®äœäžïŒãã©ã€ã¹ãã³ïŒãåŒãèµ·ããããå¯èœæ§ããããŸãã
2.2 ç®èç£çã®ã³ã³ãããŒã«
ãããã也ç¥èã®åå ãšãªããç®èãã®éããECSã«ãã£ãŠå³å¯ã«ç®¡çãããŠããŸããç®èè ºçŽ°èã«ã¯CB2å容äœãå€ãçºçŸããŠããããããç®èã®åæïŒè質çæïŒã調æŽããŠããŸãã
ç®èã¯èãä¿è·ããããã«å¿ èŠã§ãããéå°ã«åæ³ããããšççããããã®åå ãšãªããŸããéã«äžè¶³ãããšä¹Ÿç¥ãæããŸããECSã¯ããã®ç®èåæ³ããã¡ããã©è¯ããã©ã³ã¹ãã«ä¿ã€ããã®ã¹ã€ããã®ãããªåœ¹å²ãæãããŠããã®ã§ãã
3. ççãšããã¿ã®æå¶ã¡ã«ããºã
ECSãã¹ãã³ã±ã¢åéã§ç¹ã«æ³šç®ãããçç±ã¯ããã®åŒ·åãªãæççäœçšããšãé®çïŒã¡ãããïŒããã¿æ¢ãïŒäœçšãã«ãããŸãã
3.1 å ç«å¿çã®é®éå
玫å€ç·ãã¢ã¬ã«ã²ã³ã现èãªã©ã®ã¹ãã¬ã¹ã«ããããããšãç®èã®å ç«çްèãæŽ»æ§åããççæ§ãµã€ãã«ã€ã³ãšããç©è³ªãæŸåºããŸãããããèµ€ã¿ãè «ãã®åå ã§ãã
ç®èã®å ç«çްèãè§å现èã«ååšããCB2å容äœã掻æ§åããããšãéå°ãªå ç«åå¿ã«ãã¬ãŒããããããŸããããã«ãããççæ§ãµã€ãã«ã€ã³ã®æŸåºãæå¶ãããèèããé®éåã«åãããŸããECSã¯ãããã°èå éšã®ãæ¶ç«æŽ»åããè¡ã£ãŠãããšèšããŸãã
3.2 æèŠç¥çµãšããã¿ã®ãããã¯
ã¢ãããŒæ§ç®èçãææèã«ãããŠããããã¿ãã¯å€§ããªæ©ã¿ã§ããããã¿ã¯ãç®èã®æèŠç¥çµãåºæ¿ãåãåããè³ã«ä¿¡å·ãéãããšã§çããŸãã
ECSã¯ç¥çµçµæ«ã«ãäœçšããŸããç¥çµã«ååšããCB1å容äœã掻æ§åãããšãããã¿ã®ä¿¡å·äŒéãæå¶ãããããšãåãã£ãŠããŸããããã«ãããæ»ããããã«ããèããªã¢ã®ç Žå£ïŒã€ããã»ã¹ã¯ã©ããã»ãµã€ã¯ã«ïŒãæã¡åã广ãæåŸ ãããŠããŸãã
4. ç ç©¶ããŒã¿ã«èŠãECSãšæçç广
ããã§ã¯ãå®éã«ã©ã®ãããªç ç©¶çµæãåºãŠããã®ããå ·äœçãªåŠè¡è«æã«åºã¥ããŠè§£èª¬ããŸããECSã®æŽ»æ§åãå ·äœçã«ã©ã®ãããªæ°å€çå€åãããããã®ããç¥ãããšã¯éèŠã§ãã
4.1 ç®è现èã«ãããæççäœçšã®ç ç©¶
ãã³ã¬ãªãŒã®ããã¬ãã§ã³å€§åŠã§è¡ãããç ç©¶ã¯ãECSãšãããïŒå°åžžæ§ãç¡ïŒããã³ççã®é¢ä¿ã«ã€ããŠéèŠãªç¥èŠãæäŸããŠããŸãã
OláhãïŒ2014ïŒã®ç ç©¶ã«ãããšãããã®ç®èè ºçŽ°èãçšããå®éšã«ãããŠãæ€ç©æ§ã«ã³ãããã€ãïŒCBDïŒã现èå ã«ã«ã·ãŠã æ¿åºŠã®äžæãä»ããŠãéå°ãªè質åæïŒç®èã®å ïŒãæå¶ããããšã確èªãããŸãããããã«ããã®ç ç©¶ã§ã¯ããããã®åå èã®ãããªççèªçºç©è³ªã§åºæ¿ããã现èã«ãããŠãTNF-αïŒè «ç壿»å åã¢ã«ãã¡ïŒãªã©ã®ççæ§ãµã€ãã«ã€ã³ã®çºçŸãé¡èã«äœäžããããšãå ±åãããŠããŸãã
ãã®ç ç©¶çµæã¯ãECSãžã®ä»å ¥ããåã«ç®èãæ¢ããã ãã§ãªãããã§ã«èµ·ããŠããççã¬ãã«ã现èã¬ãã«ã§åŒãäžããå¯èœæ§ã瀺åããŠããŸããããã¯ãèµ€ã¿ã䌎ãèèãããæ ¢æ§çãªç®èãã©ãã«ã«å¯Ÿããæ°ããªã¢ãããŒãã®æ ¹æ ãšãªã£ãŠããŸãã
4.2 ç®èæåžžæ§ãžã®å æ¬çãªåœ±é¿
ãŸããå¥ã®å æ¬çãªã¬ãã¥ãŒè«æã§ã¯ãECSã®æ¬ æãæ©èœäžå šãã也ç¬ïŒããããïŒãã¢ãããŒæ§ç®èçã匷ç®çãªã©ã®æ§ã ãªç®èçŸæ£ã«é¢é£ããŠããããšããŸãšããããŠããŸããããŠã¹ãçšããå®éšã¢ãã«ã§ã¯ãã«ã³ãããã€ãå容äœãæ¬ æããããšãç®èã®ççåå¿ã墿ªããããå·ã®æ²»çãé ãããããããšã芳å¯ãããŠããŸãã
ãããã®äºå®ã¯ãå¥åº·ãªèãç¶æããããã«ã¯ãECSãæ£åžžã«æ©èœããŠããããšãäžå¯æ¬ ã§ããããšã匷ãè£ä»ããŠããŸãã
5. çµè«ïŒæ¬¡äžä»£ã¹ãã³ã±ã¢ãžã®ç€ºå
ãããŸã§ã®èª¿æ»ãããç®èã«ããããšã³ãã«ã³ãããã€ãã·ã¹ãã ïŒECSïŒã¯ã以äžã®3ç¹ã«ãããŠéèŠãªåœ¹å²ãæãããŠãããšçµè«ä»ããããŸãã
ããªã¢æ©èœã®ç¶æïŒ 现èã®ååãšè質åæãå©ããå€éšåºæ¿ã«åŒ·ãèãäœãã
ç®èãã©ã³ã¹ã®èª¿æŽïŒ 也ç¥ãšèæ§èã®äž¡æ¥µç«¯ãé²ããé©åºŠãªæœ€ããä¿ã€ã
ççãšããã¿ã®æå¶ïŒ å ç«åå¿ã®æŽèµ°ãæããç¥çµã¬ãã«ã§äžå¿«æãé®ããã
çŸä»£äººã®èã¯ãã¹ãã¬ã¹ãç¡ç äžè¶³ãç°å¢æ±æãªã©ã«ãããECSã®åãïŒãšã³ãã«ã³ãããã€ãã»ããŒã³ïŒãä¹±ããã¡ã§ããèæ¬æ¥ã®ãã¡ãªã¹ã¿ã·ã¹ãå°éãã现èã¬ãã«ã§ã®ä¿®åŸ©ãšé®éãæèããã±ã¢ããããããã®ã¹ãã³ã±ã¢ã®ã¹ã¿ã³ããŒããšãªãã§ãããã
6. çŸä»£ã®ã©ã€ãã¹ã¿ã€ã«ã«åãããããŒã¿ã«ã±ã¢ã®ææ¡
èšäºã§è§£èª¬ããéããèã®å¥åº·ã«ã¯ã现èã¬ãã«ã§ã®ãã©ã³ã¹ç¶æããšãååãªäŒæ¯ã«ãã修埩ããäžå¯æ¬ ã§ããããããå€å¿ãªçŸä»£ã«ãããŠãç¡ç æéã確ä¿ããè€éãªã¹ãã³ã±ã¢å·¥çšãæ¯æ¥ããªãããšã¯å®¹æã§ã¯ãããŸããã
ããã§ãç§åŠçãªç¥èŠã«åºã¥ããå¹ççãã€é«å質ãªã±ã¢ãæ±ããæ¹ã«é©ãã補åãšããŠã**ãKingly æ·±ç· ãã ãªãã¢é åãªãŒã«ã€ã³ã¯ã³ãžã§ã«ã**ã玹ä»ããŸãã
ãKingly æ·±ç·ããæäŸãã3ã€ã®ãœãªã¥ãŒã·ã§ã³
ECSãäœå ã®ãã©ã³ã¹ãæŽããããã«ããã®ãªãŒã«ã€ã³ã¯ã³ãžã§ã«ã¯å€éšããèã®ç°å¢ãæŽããçŸä»£äººã®èæ©ã¿ã«ã¢ãããŒãããŸãã
1. ç¡ç ã«çç®ããæåé å
ECSãšåæ§ãèã®ä¿®åŸ©ã¯ç¡ç äžã«æã掻çºã«è¡ãããŸããæ¬è£œåã«ã¯ãé«çŽé£æã§ãããŠã¯ãããœãŠïŒããºïŒã®ç èœãçºé µãããæ©èœæ§åæ**ããã ãªãã¢ïŒã¢ã¹ãã«ã®ã«ã¹/ãŠã¯ãããœãŠç èœçºé µæ¶²ïŒã**ãé åãããŠããŸããããã¯ç¡ç äžã®ã¹ãã³ã±ã¢ã«ç¹åããŠãããç ã£ãŠããéã«æ¥äžã®ãã¡ãŒãžãã±ã¢ããèšèšã§ãã
2. æå 端ç§åŠããšã¯ãœãœãŒã ããšããã幹现èãã®æ¡çš
èã®ãã¡ãªã¹ã¿ã·ã¹ããµããŒããããããåžå°æåã§ãã**ããšã¯ãœãœãŒã ããšããã幹现èå¹é€æ¶²ã**ã髿¿åºŠã«é åããŠããŸãããããã¯èã®ã³ã³ãã£ã·ã§ã³ãåºäžããã幎霢ãšãšãã«æ°ã«ãªãæ©ã¿ãžã¢ãããŒãããŸããããã«ãå³éžããã5çš®é¡ã®ãã¢ã«ãã³é žãšã»ã©ããããECSãæ¬æ¥ç®æããæœ€ãã®ããããªã¢æ©èœãã匷åã«ãµããŒãããŸãã
3. å¿ããæ¥åžžãæ¯ããã7圹ãã®æ©èœæ§
ç§åŠçãªã±ã¢ã¯ç¶ç¶ããŠããæå³ããããŸããæ¬è£œåã¯ãåç²§æ°Žã乳液ãçŸå®¹æ¶²ãã¯ãªãŒã ããã§ã€ã¹ããã¯ãã¢ãã¿ãŒã·ã§ãŒãããŒã·ã§ã³ããšã€ãžã³ã°ã±ã¢ã®7圹ã1æ¬ã«åçž®ããŠããŸããæ è¡ãåºåŒµãå€ãããžãã¹ãã³ã§ããããäžã€ã§å®çµãããããè·ç©ãæžããã€ã€é«å質ãªã±ã¢ãå¯èœã§ããå°éã§ã¹ããšäŒžã³ããã¯ã¹ãã£ãŒã¯ããã¿ã€ããå«ãç·æ§ããæè»œããæ±ããæ¹ã«æé©ã§ãã

èã®ççã也ç¥ããããŠãšã€ãžã³ã°ãµã€ã³ãæ°ã«ãªãæ¹ã¯ããã²ãKingly æ·±ç·ãã§ãç ã£ãŠããéã«æŽããæ·±ç·ã®ãããªå®ãããšæŽ»åãäœæããŠãã ããã
åèæç®
BÃró, T., et al. (2009). "The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities". Trends in Pharmacological Sciences, 30(8), pp.411-420.
StÀnder, S., et al. (2005). "Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus". Der Hautarzt, 56(7), pp.649-653.
Oláh, A., et al. (2014). "Cannabidiol exerts sebostatic and anti-inflammatory effects on human sebocytes". The Journal of Clinical Investigation, 124(9), pp.3713-3724.
RÃo, C.D., et al. (2018). "The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders". Biochemical Pharmacology, 157, pp.122-133.
Petrosino, S., et al. (2010). "Anti-inflammatory, anti-acne, and anti-seborrhoeic properties of N-palmitoylethanolamine and N-acylethanolamines". Experimental Dermatology, 19(10), pp.e296-e297.
#ãšã³ãã«ã³ãããã€ãã·ã¹ãã #ECS #ç®èç§åŠ #ã¹ãã³ã±ã¢ #èã®çç #èããªã¢ #也ç¥è察ç #ãããã±ã¢ #ææè #ããã¿å¯Ÿç #ãã¡ãªã¹ã¿ã·ã¹ #èæ§è #ä¿æ¹¿ã±ã¢ #ç¡ç çŸå®¹ #ã¡ã³ãºã¹ãã³ã±ã¢ #ãšã€ãžã³ã°ã±ã¢ #CBDã§ã¯ãªãäžè¬è§£èª¬ #现èã¬ãã«ã±ã¢ #å ç«ãšç®è #ã¹ãã¬ã¹ãšè #玫å€ç·ãã¡ãŒãž #çŸå®¹æå #ãã¢ã«ãã³é ž #ã»ã©ãã #ãªãŒã«ã€ã³ã¯ã³ãžã§ã« #ãã ãªã㢠#ãšã¯ãœãœãŒã é å #ãã幹现èå¹é€æ¶²é å #æçã¹ãã³ã±ã¢ #Kinglyæ·±ç·
- #ã¹ãã³ã±ã¢
- #ãšã€ãžã³ã°ã±ã¢
- #ææè
- #ãã¡ãªã¹ã¿ã·ã¹
- #ã¡ã³ãºã¹ãã³ã±ã¢
- #ä¿æ¹¿ã±ã¢
- #ãã¢ã«ãã³é ž
- #ãããã±ã¢
- #ã»ã©ãã
- #也ç¥è察ç
- #èæ§è
- #çŸå®¹æå
- #ãªãŒã«ã€ã³ã¯ã³ãžã§ã«
- #ç®èç§åŠ
- #æçã¹ãã³ã±ã¢
- #ç¡ç çŸå®¹
- #èããªã¢
- #ECS
- #ããã¿å¯Ÿç
- #玫å€ç·ãã¡ãŒãž
- #ãã ãªãã¢
- #ãšã³ãã«ã³ãããã€ãã·ã¹ãã
- #ã¹ãã¬ã¹ãšè
- #èã®çç
- #Kinglyæ·±ç·
- #现èã¬ãã«ã±ã¢
- #ãšã¯ãœãœãŒã é å
- #ãã幹现èå¹é€æ¶²é å
- #CBDã§ã¯ãªãäžè¬è§£èª¬
- #å ç«ãšç®è